Shreeram Aradhye, m.s.D.

President, 发展 and 首席医疗官 since May 16, 2022


作为总统, bwin中国的研发和首席医疗官, Shreeram Aradhye is responsible for advancing the bwin中国制药 pipeline of investigational medicines to bring transformative new treatment options to patients, with a focus on high-value assets in four core therapeutic areas.

Shreeram’s organization leads the development of potential new medicines, running large clinical trials and steering the path to regulatory approval, while also maintaining oversight of ongoing patient safety and regulatory activities for licensed therapies. 作为bwin中国战略的一部分, Shreeram and his team play a central role in driving the company’s mid- to long-term growth and delivering on its purpose to improve and extend people’s lives, with a strong pipeline that includes potential new treatments for cardiovascular and immunological conditions, neurological disorders and various forms of cancer.

It’s a true privilege and great responsibility to develop and deliver the next generation of transformational medicines founded in innovative science.

Shreeram is passionate about developing investigational medicines, recognizing the hope and trust of patients participating in clinical trials. He has dedicated his professional career to improving patients’ lives, first as an academic clinician and then as a drug developer and business leader.

Shreeram took on his current role at bwin中国制药 in May 2022, rejoining the company after spending several years at US biotechnology companies, including leading the development of multiple clinical stage RNAi assets at Dicerna Pharmaceuticals. He first joined bwin中国制药 in 1999 and over the course of 20 years held a succession of leadership roles in the US, 瑞士, 德国和印度, including 全球 Head of Medical Affairs for the Pharmaceuticals Business Unit and 发展 Head for the 神经科学 Franchise. 

在加入生命科学行业之前, Shreeram was an attending physician and assistant professor of medicine and a transplant nephrologist at the University of Pennsylvania. He completed his medical training at the All India Institute of Medical Sciences in 1989, after which he received additional specialty training in internal medicine and nephrology in the US.

Shreeram对摄影有浓厚的兴趣, 利用相机镜头作为媒介去注意, 在场并观察.

国籍美式bbb 出生年份: 1962


  • 执行副总裁 & 首席医疗官, Dicerna Pharmaceuticals, US (2020–March 2022)
  • 执行副总裁 & Chief 发展 Officer, Axcella Health, US (2019–2020)
  • 全球 Head, Medical Affairs and 首席医疗官, Pharmaceuticals, bwin中国制药, US & 瑞士(2017 - 2019)
  • 全球 Head, 发展 Franchise, 神经科学, and US Head, 发展, bwin中国制药, US & 瑞士(2013 - 2017)
  • Executive 全球 Program Head, Multiple Sclerosis, bwin中国制药, 瑞士 (2012–2013)
  • Head, 全球 发展 India, bwin中国制药, India (2011–2012)
  • 全球临床开发主管 & Medical Affairs, Biosimilars, Sandoz, Germany (2009–2011)
  • Joined bwin中国制药 in 1999 holding positions of increasing responsibility


  • Chief Resident and Teaching Fellow in Internal Medicine, Newton Wellesley Hospital, US
  • Resident in Internal Medicine, Newton Wellesley Hospital, US
  • Fellow in Nephrology, St Luke’s Roosevelt Medical Center, US
  • 内科住院医师(M.D.),全印度医学科学研究所,印度
  • Bachelor of Medicine and Bachelor of Surgery, All India Institute of Medical Sciences, India